MDMA for Headache Disorders (Cluster & Migraine)

6 papers and 0 clinical trials exploring mdma as a treatment for headache disorders (cluster & migraine).

Compoundempathogen

MDMA

MDMA is a synthetic empathogen that enhances monoamine release, producing prosocial and anxiolytic effects without frank hallucinosis. Two Phase III trials demonstrated significant PTSD symptom reductions, though FDA review raised concerns about blinding, durability, and safety characterisation.

Full MDMA profile

IndicationOver 3 billion people globally.

Headache Disorders (Cluster & Migraine)

Psychedelics are being researched as potential treatments for headache disorders, including migraines and cluster headaches, which affect a significant portion of the global population. Early findings indicate that psychedelics may modulate pain perception and offer novel therapeutic pathways for those suffering from these debilitating conditions.

Full Headache Disorders (Cluster & Migraine) profile

Academic Research

6 papers

Open Accessindividual

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

In a multicentre, double‑blind, placebo‑controlled phase 2 trial of 65 adults with chronic PTSD, once‑weekly oral TSND‑201 produced significantly greater reductions in clinician‑rated PTSD severity (CAPS‑5; LS mean difference 9.64, P = .01) and improvements in self‑reported symptoms, functioning and depression versus placebo. TSND‑201 was generally well tolerated — common adverse events included headache, decreased appetite, nausea, dizziness and transient blood‑pressure increases — supporting its potential as a rapid‑acting, durable treatment for PTSD.

Published: February 18, 2026
Journal: JAMA Psychiatry
Authors: Jones, A., Warner-Schmidt, J., Kwak, H., Stogniew, M., Mandell, B., Ching, T. H., Stein, M. B., Kelmendi, B.

Open Accessmeta

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review

This mixed-methods systematic review of 44 clinical studies (598 patients) found serotonergic psychedelics and MDMA to be generally well tolerated but noted that adverse events were poorly defined and likely underreported. Common acute AEs were nausea, headache and anxiety, late AEs included fatigue and low mood, one serious MDMA-related cardiac event occurred, and qualitative data suggest challenging psychological experiences can also have therapeutic value, underlining the need for systematic, detailed AE assessment in future trials.

Published: August 26, 2022
Journal: Journal of Psychopharmacology
Authors: Breeksema, J. J., Kuin, B. W., Kamphuis, J., Van Den Brink, W., Vermetten, E., Schoevers, R. A.

Open Accessmeta

Hallucinogenic Persisting Perception Disorder: A Case Series and Review of the Literature

This retrospective series of 13 patients and review of 24 case reports found that HPPD commonly causes visual snow, floaters, palinopsia, photophobia and nyctalopia despite normal ophthalmic and neurological investigations, producing a phenotype that overlaps substantially with Visual Snow Syndrome. The authors argue DSM‑5 diagnostic criteria should be expanded to include these symptoms, that VSS patients be screened for prior hallucinogen use, and that controlled studies compare primary and secondary VSS to clarify pathophysiology and treatment.

Published: May 6, 2022
Journal: Frontiers in Neurology
Authors: Van Der Walt, A., Ford, H., Fraser, C. L., Solly, E., Clough, M., Fielding, J., White, O.

Paywallmeta

MDMA-assisted psychotherapy for treatment of post-traumatic stress disorder: a systematic review with meta-analysis

This systematic review (2021) entails a meta-analysis of the current literature on MDMA-assisted therapy for the treatment of PTSD. It was found that MDMA significantly reduced CAPS scores and is generally safe and well tolerated although side effects such as headache and nausea are commonly reported.

Published: October 28, 2021
Journal: Journal of Clinical Pharmacology
Authors: Smith, K. W., Sicignano, D. J., Hernandez, A. V., White, M.

Open Accessmeta

Psychedelics

This paper is the most comprehensive review of psychedelics research up to 2016 by the eminent David E. Nichols.

Published: April 1, 2016
Journal: Pharmacological Reviews
Authors: Nichols, D. E.

Open Accessindividual

User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study

This survey study (n=626) investigated user perceptions of the benefits and harms of using LSD, psilocybin, MDMA, cannabis, ketamine, and alcohol. Overall, LSD and psilocybin were regarded as having the most positive impact on wellbeing, and the least harms in terms of physical and mental health.

Published: July 30, 2010
Journal: Journal of Substance Use
Authors: Carhart-Harris, R. L., Nutt, D. J.

Clinical Trials

0 trials

No clinical trials have been tagged with both MDMA and Headache Disorders (Cluster & Migraine) yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all MDMA papers Search all Headache Disorders (Cluster & Migraine) trials Full MDMA profile Full Headache Disorders (Cluster & Migraine) profile

Company

Product

Legal

MDMA for Headache Disorders (Cluster & Migraine)

MDMA

Headache Disorders (Cluster & Migraine)

Academic Research

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review

Hallucinogenic Persisting Perception Disorder: A Case Series and Review of the Literature

MDMA-assisted psychotherapy for treatment of post-traumatic stress disorder: a systematic review with meta-analysis

Psychedelics

User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study

Clinical Trials

Explore further